Literature DB >> 21326033

Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer.

Berit Maria Müller1, Ralf Kronenwett, Guido Hennig, Heike Euting, Karsten Weber, Kerstin Bohmann, Wilko Weichert, Gabriela Altmann, Claudia Roth, Klaus-Jürgen Winzer, Glen Kristiansen, Christoph Petry, Manfred Dietel, Carsten Denkert.   

Abstract

The development of optimized therapy strategies against malignant tumors is critically dependent on the assessment of tissue-based biomarkers in routine diagnostic tissue samples. We investigated a novel, fully automated, and xylene-free method for RNA isolation and biomarker determination using formalin-fixed paraffin-embedded (FFPE) tissue. The aim was to show that this approach is feasible and gives results that are comparable to the current gold standards. Expression of the breast cancer biomarkers ESR1, PGR, and HER2 was measured in a total of 501 FFPE tissue samples from 167 breast carcinomas, which had been stored for up to 21 years. Total RNA was extracted from tissue sections and biomarker expression was measured by kinetic RT-PCR (RT-kPCR). The results of the new method were compared with immunohistochemistry as the current gold standard.RNA was successfully isolated from all samples, with a mean yield of 1.4 μg/sample and fragment lengths of at least 150 bp in 99% of samples. RT-kPCR analysis of ESR1, PGR, and HER2 was possible in all samples. Comparing RT-kPCR results with standard IHC, we found a good concordance for ESR1 (agreement: 98.4%), PGR (84.4%), and HER2 (89.8%). We observed a low section-to-section variability of kPCR results for all 3 biomarkers (root of mean squared errors: 0.2 to 0.5 Ct values). The new approach is a reliable high-throughput instrument for standardized testing of biomarkers in clinical routine and for research studies on archived FFPE material up to 21 years old. For the assessment of ESR1, PGR, and HER2 the results are comparable to the current gold-standard.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21326033     DOI: 10.1097/PDM.0b013e3181e3630c

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  43 in total

Review 1.  Quality assurance of RNA expression profiling in clinical laboratories.

Authors:  Weihua Tang; Zhiyuan Hu; Hind Muallem; Margaret L Gulley
Journal:  J Mol Diagn       Date:  2011-10-20       Impact factor: 5.568

2.  In stage II/III lymph node-positive breast cancer patients less than 55 years of age, keratin 8 expression in lymph node metastases but not in the primary tumour is an indicator of better survival.

Authors:  Serena Bonin; Danae Pracella; Renzo Barbazza; Sandro Sulfaro; Giorgio Stanta
Journal:  Virchows Arch       Date:  2015-02-28       Impact factor: 4.064

Review 3.  [Gene expression analysis in breast cancer. A new diagnostic tool in pathology].

Authors:  C Denkert
Journal:  Pathologe       Date:  2013-09       Impact factor: 1.011

4.  Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.

Authors:  C Brüggemann; M C Kirchberger; S M Goldinger; B Weide; A Konrad; M Erdmann; D Schadendorf; R S Croner; L Krähenbühl; K C Kähler; C Hafner; W Leisgang; F Kiesewetter; R Dummer; G Schuler; M Stürzl; L Heinzerling
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-14       Impact factor: 4.553

5.  Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years.

Authors:  Berit M Pfitzner; Bianca Lederer; Judith Lindner; Christine Solbach; Knut Engels; Mahdi Rezai; Karel Dohnal; Hans Tesch; Martin L Hansmann; Christoph Salat; Michaela Beer; Andreas Schneeweiss; Peter Sinn; Agnes Bankfalvi; Silvia Darb-Esfahani; Gunter von Minckwitz; Bruno V Sinn; Ralf Kronenwett; Karsten Weber; Carsten Denkert; Sibylle Loibl
Journal:  Mod Pathol       Date:  2017-12-22       Impact factor: 7.842

Review 6.  Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy.

Authors:  Lokesh Agrawal; Kelly B Engel; Sarah R Greytak; Helen M Moore
Journal:  Semin Cancer Biol       Date:  2017-12-16       Impact factor: 15.707

7.  Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies.

Authors:  J Michael Dixon; David A Cameron; Laura M Arthur; Deborah M Axelrod; Lorna Renshaw; Jeremy S Thomas; Arran Turnbull; Oliver Young; Cynthia A Loman; Debbie Jakubowski; Frederick L Baehner; Baljit Singh
Journal:  Adv Ther       Date:  2019-03-11       Impact factor: 3.845

8.  Spatially multiplexed RNA in situ hybridization to reveal tumor heterogeneity.

Authors:  Lena Voith von Voithenberg; Anna Fomitcheva Khartchenko; Deborah Huber; Peter Schraml; Govind V Kaigala
Journal:  Nucleic Acids Res       Date:  2020-02-20       Impact factor: 16.971

9.  Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts.

Authors:  Carsten Denkert; Bruno Valentin Sinn; Yasmin Issa; Berit Maria Müller; Andrea Maisch; Michael Untch; Gunter von Minckwitz; Sibylle Loibl
Journal:  Breast Care (Basel)       Date:  2011-08-29       Impact factor: 2.860

10.  Expression and localization of axin 2 in colorectal carcinoma and its clinical implication.

Authors:  Ute Schaal; Sandra Grenz; Susanne Merkel; Tilman T Rau; Michel V Hadjihannas; Elisabeth Kremmer; Priya Chudasama; Roland S Croner; Jürgen Behrens; Michael Stürzl; Elisabeth Naschberger
Journal:  Int J Colorectal Dis       Date:  2013-05-24       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.